In this fifth installment, Laura R. Bobolts, PharmD, BCOP, and Lisa Raff, MSPharm, BCPS, BCOP, discuss payer considerations when considering reimbursement and formulary inclusion of bispecific agents, as well as how payers keep up-to-date on the evolving landscape of multiple myeloma learning opportunities from bispecific therapy REMS programs.
In this fourth installment, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss operational considerations and potential learning opportunities from bispecific therapy REMS programs.
In this third installment, Hakan Kaya, MD, Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, and Yonatan Resnick, PharmD, discuss considerations for adopting bispecific therapies into regular multiple myeloma clinical practice.
In this second installment, Hakan Kaya, MD, and Yonatan Resnick, PharmD, discuss staff educational needs and experiences implementing staff education for bispecific agents in multiple myeloma.
In this first installment, Hakan Kaya, MD, and Kristen Boykin, PharmD, RPh/CPh, BCOP, BCPS, discuss processes and experiences in transitions of care for multiple myeloma patients.